{"id":783289,"date":"2023-09-12T06:46:41","date_gmt":"2023-09-12T10:46:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/"},"modified":"2023-09-12T06:46:41","modified_gmt":"2023-09-12T10:46:41","slug":"affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/","title":{"rendered":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">AFM13 in combination with AlloNK\u00ae (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed\/refractory Hodgkin lymphoma<\/li>\n<li style=\"margin-bottom:8pt\">The FDA\u2019s fast track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need<\/li>\n<\/ul>\n<p>MANNHEIM, Germany, Sept.  12, 2023  (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE\u00ae) AFM13 with AlloNK\u00ae for the potential treatment of relapsed\/refractory (r\/r) Hodgkin lymphoma (HL). The combination treatment is entering Phase 2 development and will be investigated in Affimed\u2019s LuminICE-203 study (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jadrk03hFw__B-zMT_nGM0TxH3fPfBgRuhjPFs8LttIdZeG6COwRo2tO1bm316fqb7L184-GTzvhyBfMoQM9LtI1HJepIn02yReMypjlVdXNxb4cm6boZByXAfE322uOsc6x_oJsfjhEcTsRPwcrTPGVHuTZwuVlSc0AmJPSzf8=\" rel=\"nofollow noopener\" target=\"_blank\">NCT05883449<\/a>), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.<\/p>\n<p>\u201cOur clinical data of AFM13 in combination with allogeneic NK cells has shown outstanding efficacy and a well-managed safety profile in late-stage, muti-refractory, patients with r\/r Hodgkin and Non-Hodgkin lymphoma,\u201d said Dr. Wolfgang Fischer, Chief Operating Officer at Affimed. \u201cThe FDA fast track designation is a testament to the powerful potential our combination approach may deliver for these patients in high need, and we remain committed to working closely with the FDA to expedite development of this important therapy.\u201d<\/p>\n<p>Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs that are intended to treat or prevent serious conditions and have the potential to address an unmet medical need. The FDA\u2019s decision is based on available data showing the potential of the AFM13 and AlloNK\u00ae combination therapy to overcome current limitations in the treatment of r\/r HL. With the Fast Track Designation, the therapeutic development of the combination can benefit from more frequent engagement with the FDA, which will support the collection of appropriate data needed to accelerate its development.<\/p>\n<p>LuminICE-203 builds on the clinical findings from the phase 1\/2 AFM13-104 trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=35VFe2pgVj-0t7XzSWDJOIsm8OAZUjPEKmQJzp4LhS4m4XFNMjJotKXAYbtmf8wWH5Fc92_1FbZ4XMjNmtRFvGgLdzoMw_rMPyCAgTRCRDfDCbSO5V11LjlSQ23AMcf2vBpSYF_5fJq-omh0yby4xA==\" rel=\"nofollow noopener\" target=\"_blank\">NCT04074746<\/a>), in which investigators assessed AFM13 in combination with cord blood-derived natural killer cells in heavily pretreated patients with CD30-positive Hodgkin lymphoma and non-Hodgkin lymphoma. Data presented to date from this trial have shown outstanding clinical results in late-stage, multi-refractory, patients with a 94% overall response rate (ORR), a 71% complete response (CR) rate and a well-managed safety profile at the recommended phase 2 dose (RP2D); specifically in the 31 r\/r HL patients treated, the ORR and CR were 97% and 77% respectively (see press release <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DZajC1RSIhXjOyLhiC9YJpz40IWo4RpgxXsRVq-spXuXwilVbu68WHY5zA8m6xN9w9jd0hg3v-F8B5TQZExnkJyjz1gF9mfbdnC5cXqH8fxz_1yE9xZkc9GvlNMxQKo047gf9fgQV9IKUbVJAISPMYEI_skMyQheXC7YRGhwYRfWS1dNJPtYObHspjXoDhnJHrx5sPNpXAh82wt-xNauxONJ15N7bgM75i0W6x48ihQc4MFRPjW4Xx8q0Qoqf-Dp15MsZqvzzq5W_IQi_Ud15Q==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>).<\/p>\n<p>\n        <strong>About FDA Fast Track Designation<\/strong>\n      <\/p>\n<p>Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Its purpose is to get important new drugs to patients earlier. Fast Track addresses a broad range of serious conditions.<\/p>\n<p>With Fast Track Designation, a new therapy is eligible for some or all of the following:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">More frequent meetings with FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval<\/li>\n<li style=\"margin-bottom:8pt\">More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers<\/li>\n<li style=\"margin-bottom:8pt\">Eligibility for\u00a0Accelerated Approval and Priority Review, if relevant criteria are met<\/li>\n<li style=\"margin-bottom:8pt\">Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA<\/li>\n<\/ul>\n<p>Please refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vpYLVl142Kz_RhOWgWLvoXMfXiwr2DhhzdtrY3AOsD1_NVWCvlnxG79rRQYGM-6lW1-x19L1o0ih7K1c6TGA8hn4j7oKi7IbfM6o2jLdDHQNAWGNesKJN_ibGu2Y5geFpoUYAxloLQmWLiVCb19h14pLyUH9CyHuJ3mgRAdSe2VbrriW-FB4VgbiuaRnFTqpwFIgprGXtb_ne3aCQfhfuw==\" rel=\"nofollow noopener\" target=\"_blank\">Fast Track | FDA<\/a> for further information.<\/p>\n<p>\n        <strong>About AFM13 <\/strong>\n      <\/p>\n<p align=\"justify\">AFM13 is a first-in-class innate cell engager (ICE\u00ae) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is Affimed\u2019s most advanced ICE\u00ae clinical program and was evaluated as monotherapy in a phase 2B trial in patients with relapsed\/refractory peripheral T cell lymphoma (REDIRECT). Additional details can be found at www.clinicaltrials.gov (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=35VFe2pgVj-0t7XzSWDJOHbOhxi9WLbk-ejl0WvXxdSFdN4WtCoEV8EDvsZaAAhPrPeXuWfzjRr2t24qr2mYyuj6qtg-tfox8DXRKUjqSmWO9TI0Xi_C4_xvgpXCvWJIBqjt0MxjVmd71jO_z3kbMg==\" rel=\"nofollow noopener\" target=\"_blank\">NCT04101331<\/a>). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells.<\/p>\n<p>\n        <strong>About Affimed N.V. <\/strong>\n      <\/p>\n<p>Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company\u2019s proprietary ROCK\u00ae platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK\u00ae platform predictably generates customized innate cell engager (ICE\u00ae) molecules, which use patients\u2019 immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE\u00ae. Headquartered in Mannheim, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the Company\u2019s people, pipeline and partners, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LsnCKiVQSfmw0LFtkPXYz1AjjlpOBc656YyiRAKrNoHYMfVklfNtHRuzvAQkRDBgoeX-3rh87Fi1M9Hgc27kxw==\" rel=\"nofollow noopener\" target=\"_blank\">www.affimed.com<\/a>.<\/p>\n<p>\n        <strong>About AlloNK\u00ae<\/strong>\n      <\/p>\n<p>AlloNK\u00ae (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK\u00ae in a Phase 1\/2 multicenter clinical trial (ClinicalTrials.gov Identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=35VFe2pgVj-0t7XzSWDJOIsziTDIne8zipCC-EVOxjFYOixZbwj18xs6i4H5RKZvl21ipeVmWDoiEJ8RuS59H8DVIf1taeJLdO9mGXqArLoZVVHIZJw1Miqq3UUixCI8\" rel=\"nofollow noopener\" target=\"_blank\">NCT04673617<\/a>) to assess the safety and clinical activity of AlloNK\u00ae alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK\u00ae in combination with rituximab in patients with lupus nephritis. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DabyVscNM9Hm42kx15y02DfFBGf5KPTlGimKNWA1tbRIM2kP2gFQlZr-RqD8wCiKAO2Zf8XLfxMHb9VBWSURfq0NJPX_iWAyHjufqiCkQ3Y4PPvG08cvdm02r5uBt6UFH-4FhG3MmMKGU_oZYdhvGg==\" rel=\"nofollow noopener\" target=\"_blank\">cell therapy manufacturing platform<\/a>, Artiva can generate thousands of doses of AlloNK\u00ae from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK\u00ae is being administered in the outpatient setting over multiple doses and multiple cycles.<\/p>\n<p>\n        <strong>About Artiva Biotherapeutics<\/strong>\n      <\/p>\n<p>Artiva\u2019s mission is to deliver highly effective, off-the-shelf, allogeneic NK cell-based therapies that are safe and accessible to patients. Artiva has taken a Manufacturing-First approach to create a highly scaled process integrating cell expansion, activation, and engineering technology developed by Artiva\u2019s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva\u2019s pipeline includes AlloNK\u00ae, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva\u2019s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates. Artiva is headquartered in San Diego. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LsnCKiVQSfmw0LFtkPXYzy2KTzH7YZSo_zUoGfoNlZvdlVLQlV45fUiTJUtxT4ELvfKnP5uLk5hc7Yf_zOsBodCwRWDt7joHUECcblSyNc8=\" rel=\"nofollow noopener\" target=\"_blank\">www.artivabio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding the Company\u2019s intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM13, AFM24, AFM28 and the Company\u2019s other product candidates, the value of its ROCK\u00ae platform, its ongoing and planned preclinical development and clinical trials, its collaborations and development of its products in combination with other therapies, the timing of and its ability to make regulatory filings and obtain and maintain regulatory approvals for its product candidates, its intellectual property position, its collaboration activities, its ability to develop commercial functions, clinical trial data, its results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which it operates, the macroeconomic trends that may affect the industry or the Company, such as the instability in the banking sector experienced in the first quarter of 2023, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation, the impact on its business by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties, such as the Russia-Ukraine conflict, the fact that the current clinical data of AFM13 in combination with NK cell therapy is based on AFM13 precomplexed with fresh allogeneic cord blood-derived NK cells from The University of Texas MD Anderson Cancer Center, as opposed to Artiva\u2019s AlloNK\u00ae and other uncertainties and factors described under the heading \u201cRisk Factors\u201d in Affimed\u2019s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/p>\n<p align=\"justify\">\n        <strong>Affimed Investor Relations Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Alexander Fudukidis<br \/>Director, Investor Relations<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RSWEMEtP6g94i27wZQsBXO8j8MR_RXQep5p6tAqOvAXDxapK9XLuDYUgMy2XGNfXPWQkaPOG_kkM9XbI7SuXNagWEiyJkuTVl4YvZ954Cys=\" rel=\"nofollow noopener\" target=\"_blank\">a.fudukidis@affimed.com<\/a><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p align=\"justify\">\n        <strong>Affimed Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Mary Beth Sandin <br \/>Vice President, Marketing and Communications<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bnFFLv3zFV2bB7rvigMMG8gOIqi2HAaKZTKspZXolSuDXZIAj2wzYBe5_gheszWFZJpol06L2bxqJli17tzTVqn7QteWewUOKQdd1Da5vSI=\" rel=\"nofollow noopener\" target=\"_blank\">m.sandin@affimed.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Artiva Investor Relations Contact<\/strong><br \/>\n        <br \/>Nicholas Veomett, Ph.D. <br \/>Executive Director, Corporate Development<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YiQ5evOb9hdt6q34DzGEDaFSatbIfAYOyB9dMTSLHcyCAuyV6eG_QhqGRMLs85XUfVQ3mlAN_megjKU21XKRwUBmbkrNHXkYvQy65iiLMts=\" rel=\"nofollow noopener\" target=\"_blank\">ir@artivabio.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Artiva Media Contact<\/strong><br \/>\n        <br \/>Jessica Yingling, Ph.D. <br \/>Little Dog Communications Inc.<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AGfaxYxTh2mSJPil-XyRbW-gkyPiCuHdSyIEr4VN12ohnZaBUEubXh0fteO7DKj8prngiWgjkfHfzgYUVyCHbLbM7GWH5t4c9_DTDetNVI4=\" rel=\"nofollow noopener\" target=\"_blank\">jessica@litldog.com<\/a><br \/>Tel.: +1 (858) 344-8091<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTIzNTk1N2ItNTVlYi00OThiLTlkYjAtYzEyOTI3YTIxYTM5LTEwMTUzMDc=\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AFM13 in combination with AlloNK\u00ae (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed\/refractory Hodgkin lymphoma The FDA\u2019s fast track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need MANNHEIM, Germany, Sept. 12, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE\u00ae) AFM13 with AlloNK\u00ae for the potential &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783289","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AFM13 in combination with AlloNK\u00ae (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed\/refractory Hodgkin lymphoma The FDA\u2019s fast track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need MANNHEIM, Germany, Sept. 12, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE\u00ae) AFM13 with AlloNK\u00ae for the potential &hellip; Continue reading &quot;Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-12T10:46:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma\",\"datePublished\":\"2023-09-12T10:46:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/\"},\"wordCount\":1668,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/\",\"name\":\"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\",\"datePublished\":\"2023-09-12T10:46:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk","og_description":"AFM13 in combination with AlloNK\u00ae (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed\/refractory Hodgkin lymphoma The FDA\u2019s fast track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need MANNHEIM, Germany, Sept. 12, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE\u00ae) AFM13 with AlloNK\u00ae for the potential &hellip; Continue reading \"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-12T10:46:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma","datePublished":"2023-09-12T10:46:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/"},"wordCount":1668,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/","name":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=","datePublished":"2023-09-12T10:46:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMDM0NCM1ODA5MjI3IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783289"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}